
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE has demonstrated strong financial performance, with product sales increasing by 13% year-over-year, contributing to total revenue of €169.6 million in 2024, which reflects a 10% increase from 2023. Despite slower-than-expected initial sales for the Ixchiq vaccine in the U.S., the company is optimistic, anticipating that Ixchiq sales will surpass €100 million in its third year of commercialization, alongside a predicted global market exceeding $500 million annually for chikungunya vaccines. Moreover, recent regulatory approvals for Ixchiq in both the U.S. and EU bolster the company's confidence in its ability to achieve key developmental milestones while maintaining a healthy cash runway.
Bears say
Valneva SE is anticipated to confront significant financial challenges, as the company aims to reduce its operating cash burn to less than €30 million in 2025, down from over €60 million in 2024, indicating a tight financial environment. Furthermore, the company's revenue estimates for 2025 have been revised downward to €185 million from €222.5 million, reflecting declining sales projections for its vaccine candidate IXCHIQ. The adjusted earnings per share (EPS) forecast for 2025 has also been lowered to (€0.65) from (€0.53), underscoring the overall negative outlook concerning its financial performance.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares